Patent · US Active

Antibodies binding to NKG2D

US11827711B2 · kind B2 · utility

0Cited by

0References

27Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Stefan Dengl · Munich, DE
Guy Georges · Habach, DE
Ralf Hosse · Baar, CH
Inja Waldhauer · Schlieren, CH
Christian Klein · Iffeldorf, DE
Pablo Umana · Wollerau, CH

Key dates

Filing date	Jul 14, 2020
Grant date	Nov 28, 2023
Priority date	—
Expiry date	Apr 23, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.